Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
  • A61K38/22—Hormones
  • A61K38/28—Insulins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
  • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
  • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention is directed to nanoparticulate compositions comprising insulin, having adsorbed to the surface of the insulin particles at least one surface stabilizer.
• Nanoparticulate compositions are particles consisting of a poorly soluble active agent having adsorbed onto the surface thereof a non-crosslinked surface stabilizer.
• the '684 patent also describes methods of making such nanoparticulate compositions. Nanoparticulate compositions are desirable because with a decrease in particle size, and a consequent increase in surface area, a composition is rapidly dissolved and absorbed following administration.
• the '684 patent does not teach or suggest nanoparticulate compositions comprising peptides or insulin.
• Nanoparticulate compositions are also described, for example, in U.S. Patent Nos. 5,298,262 for "Use of Ionic Cloud Point Modifiers to Prevent Particle Aggregation During Sterilization;" 5,302,401 for “Method to Reduce Particle Size Growth During Lyophilization;” 5,318,767 for “X-Ray Contrast Compositions Useful in Medical Imaging;” 5,326,552 for “Novel Formulation For Nanoparticulate X-Ray Blood Pool Contrast Agents Using High Molecular Weight Non-ionic Surfactants;” 5,328,404 for “Method of X-Ray Imaging Using Iodinated Aromatic Propanedioates;” 5,336,507 for “Use of Charged Phospholipids to Reduce Nanoparticle Aggregation;” 5,340,564 for “Formulations Comprising Olin 10-G to Prevent Particle Aggregation and Increase Stability;” 5,346,702 for "Use of Non-Ionic Cloud Point Mod
• Nanoparticulate peptides and proteins are referenced in U.S. Patent No. 6,375,986 for "Solid Dose Nanoparticulate Compositions Comprising a Synergistic Combination of a Polymeric Surface Stabilizer and Dioctyl Sodium Sulfosuccinate," U.S. Patent No. 6,428,814 for "Bioadhesive Nanoparticulate Compositions Having Cationic Surface Stabilizers," U.S. Patent Application No.
• Amorphous small particle compositions are described, for example, in U.S. Patent Nos. 4,783,484 for "Particulate Composition and Use Thereof as Antimicrobial Agent;” 4,826,689 for “Method for Making Uniformly Sized Particles from Water-Insoluble Organic Compounds;” 4,997,454 for “Method for Making Uniformly-Sized Particles From Insoluble Compounds;” 5,741,522 for "Ultrasmall, Non-aggregated Porous Particles of Uniform Size for Entrapping Gas Bubbles Within and Methods;” and 5,776,496, for "Ultrasmall Porous Particles for Enhancing Ultrasound Back Scatter.” None of these references relates to a nanoparticulate insulin composition.
• U.S. Patent No. 5,889,110 discloses microparticles comprising a salt formed from a cation derived from a peptide containing one or more basic groups and an anion derived from a carboxy-terminated polyester.
• the composition is prepared from a stoichiometric equivalent of the polyester carboxylic acid end groups relative to the basic peptide groups, obtainable by a complicated and expensive process.
• Such a process comprises: (i) dissolving the basic peptide and carboxy-terminated polyester in a first solvent in which both the peptide and the polyester are soluble to form a first solution; (ii) freezing the first solution at high speed to form a frozen mixture; (iii) freeze-drying the frozen mixture to remove the first solvent to form a freeze-dried product; (iv) dispersing the freeze-dried product into a second solvent which is a solvent for the polyester and a non-solvent for the peptide to form a second solution containing the peptide/polyester salt; and (v) removing the second solvent from the second solution by spray-drying, spray-congealing, evaporation, or phase separation coacervation to form a microparticulate solid product.
• U.S. Patent No. 5,354,562 discloses a process for preparing micronized polypeptide drugs in a powder form suitable for aerosol administration or for use in injectable suspensions by lyophilization followed by jet milling.
• U.S. Patent No. 6,051,694 discloses a method of size reduction of proteins comprising contacting the solid protein with a critical fluid in which the protein is essentially insoluble, followed by depressurization of the protein and critical fluid mixture.
• the present invention is directed to the surprising and unexpected discovery that stable nanoparticulate compositions of insulin can be made.
• the nanoparticulate compositions which comprise insulin and at least one surface stabilizer adsorbed to the surface thereof, are advantageous in comparison to prior art insulin preparations in that they possess both a rapid onset of activity and prolonged activity.
• the invention is further directed to methods of making nanoparticle insulin compositions and pharmaceutical dosage forms containing them.
• the method of preparing the insulin compositions comprises contacting insulin, e.g. insoluble bovine insulin or recombinant insulin, with at least one surface stabilizer for a time and under conditions sufficient to provide a stable nanoparticulate composition.
• the particle size of insulin is reduced by milling or homogenization.
• the one or more surface stabilizers can be contacted with the insulin either before, during, or after size reduction thereof.
• the present invention is further directed to treatment of conditions requiring insulin therapy.
• FIG 1 Are scanning electron microscope images at 5,000 magnification of insulin particles before and after milling in accordance with the method of the present invention
• FIG 2 Shows the results of a reducing SDS PAGE gel of the supernatant and pellet of a nanoparticulate insulin sample in two concentrations to determine whether milling caused a loss of insulin;
• FIG 3 Shows the results of a reducing SDS PAGE gel of the pellet of a nanoparticulate insulin sample in two concentrations to determine whether milling caused a loss of insulin;
• FIG 4 Shows the pharmacokinetic parameters of insulin resulting from injection of nanoparticulate insulin samples via intramuscular, subcutaneous and intraperitoneal routes in comparison to a control insulin solution:
• FIG 5 Is a bar graph illustrating the AUC ( ⁇ U/ml.h) of insulin from injection of nanoparticulate insulin samples via subcutaneous, intramuscular and intraperitoneal routes in comparison to a control insulin solution
• FIG. 6 Is a plot showing blood insulin concentration over time following injection of nanoparticulate insulin samples via subcutaneous, intramuscular and intraperitoneal routes in comparison to a reference insulin solution
• FIG. 7 Is a plot showing blood glucose concentration over time following injection of nanoparticulate insulin samples via subcutaneous, intramuscular and intraperitoneal routes in comparison to a reference insulin solution
• FIG. 8 Is a plot showing the change in blood glucose concentration over time following injection of nanoparticulate insulin samples via subcutaneous, intramuscular and intraperitoneal routes in comparison to a reference insulin solution.
• the present invention is directed to compositions of nanoparticulate insulin and methods for their preparation and use in insulin therapy.
• crystalline drags could be formulated into nanoparticulate compositions by the method taught in the '684 patent.
• formulations of nanoparticulate insulin were not contemplated, partly due to the difficulty in retaining the insulin conformational structure upon milling to a particle size in the nanometer region. This is significant, as a change in conformation of insulin can correlate with a loss of activity.
• Nanoparticulate insulin prepared in accordance to the present invention, comprises at least one surface stabilizer that is adsorbed to the insulin particles.
• the surface stabilizer acts as a steric barrier to other insulin particles thereby preventing agglomeration and particle size growth. This results in a stable nanoparticulate composition, in which the particle size of the composition does not significantly increase over time via solubilization and recrystallization or agglomeration.
• Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular crosslinkages.
• Insulin is a 5.8 kD protein hormone important in regulation of fuel metabolism. Secretion of insulin by the ⁇ cells of the pancreas is stimulated by glucose and the parasympathetic nervous system. Insulin promotes the dephosphorylation of key interconvertible enzymes. One consequence is to stimulate glycogen synthesis in both muscle and liver and to suppress gluconeogenesis by the liver. Insulin also accelerates glycolysis in the liver, which in turn increases the synthesis of fatty acids. The entry of glucose into muscle and adipose cells is promoted by insulin. The abundance of fatty acids and glucose in adipose tissue results in the synthesis and storage of triacylglycerols. The action of insulin also extends to amino acid and protein metabolism. Insulin promotes the uptake of branched-chain amino acids by muscle, which favors a building up of muscle protein. In sum, insulin has a general stimulating effect on protein synthesis.
• compositions of insulin Three different compositions of insulin are available: soluble, insoluble, and a mixture thereof. The difference among these compositions is in the observed bioavailability at physiological conditions.
• Insoluble insulin, and a mixture of soluble and insoluble insulin have a slow onset of activity, about 2 hours, but a prolonged duration that extends for up to about 24 and 13-14 hours, respectively.
• Soluble insulin has a more rapid onset of activity, about 30 minutes, but with only about six hours duration of activity.
• the nanoparticle insulin of the present invention is superior to prior art insulin compositions in that it displays a rapid onset of activity, such as that found with soluble insulin, and it exhibits a prolonged duration of activity, such as that found in insoluble and soluble-insoluble insulin mixtures.
• the insulin composition can be formulated for administration via, for example, oral, pulmonary, nasal, parenteral, rectal, local, buccal, or topical administration.
• the insulin particles can be in the form of crystalline particles, semi-crystalline particles, semi-amorphous particles, amorphous particles, or a mixture thereof.
• the concentration of insulin in the compositions of the invention can vary from about 99.5% to about 0.001%, from about 95% to about 0.1%, or from about 90% to about 0.5%, by weight, based on the total combined dry weight of the insulin and at least one surface stabilizer, not including other excipients.
• Suitable surface stabilizers utilized in preparing the subject nanoparticle insulin are preferably selected from known organic and inorganic pharmaceutical excipients. Two or more surface stabilizers may be used in combination. The surface stabilizers protect insulin from degradation and potential protease cleavage in addition to preventing agglomeration and particle size growth as described above.
• Such organic and inorganic pharmaceutical excipients include various polymers, low molecular weight oligomers, natural products, and surfactants.
• Preferred surface stabilizers include nonionic and ionic surfactants (e.g., cationic and anionic surfactants).
• surface stabilizers include cetyl pyridinium chloride, gelatin, lecithin (phosphatides), dextran, glycerol, cholesterol, tragacanth, stearic acid, its salts and its esters, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, e.g., the commercially available Tweens® such as Tween 80® (ICI Specialty Chemicals); polyethylene glycols, e.g., Carbowaxs 3350® and 1450®, and Carbopol 934® (Union Carbide), dodecyl trimethyl ammonium bromide, polyoxyethylene stearates, colloidal silicon dioxide, sodium dodecylsulfate, carboxymethylcellulose calcium, hydroxypropyl celluloses (e.g., HPC, HPC-SL, andHPC-L)
• cationic surface stabilizers include, but are not limited to, polymers, biopolymers, polysaccharides, cellulosics, alginates, phospholipids, and nonpolymeric compounds, such as zwitterionic stabilizers, poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole, polybrene, polymethylmethacrylate trimethylammoniumbromide bromide (PMMTMABr), hexyldesyltrimethylammonium bromide (HDMAB), and polyvinylpyrrolidone-2- dimethylaminoethyl methacrylate dimethyl sulfate.
• zwitterionic stabilizers poly-n-methylpyridinium, anthryul pyridinium chloride, cationic phospholipids, chitosan, polylysine, polyvinylimidazole
• cationic stabilizers include, but are not limited to, cationic lipids, sulfonium, phosphonium, and quarternary ammonium compounds, such as stearyltrimethylammonium chloride, benzyl-di(2-chloroethyl)ethylammonium bromide, coconut trimethyl ammonium chloride or bromide, coconut methyl dihydroxyethyl ammonium chloride or bromide, decyl triethyl ammonium chloride, decyl dimethyl hydroxyethyl ammonium chloride or bromide, C 12- 15 dimethyl hydroxyethyl ammonium chloride or bromide, coconut dimethyl hydroxyethyl ammonium chloride or bromide, myristyl trimethyl ammonium methyl sulphate, lauryl dimethyl benzyl ammonium chloride or bromide, lauryl dimethyl (ethenoxy) 4 ammonium chloride or bromide, N-
• Such exemplary cationic surface stabilizers and other useful cationic surface stabilizers are described in J. Cross and E. Singer, Cationic Surfactants: Analytical and Biological Evaluation (Marcel Dekker, 1994); P. and D. Rubingh (Editor), Cationic Surfactants: Physical Chemistry (Marcel Dekker, 1991); and J. Richmond, Cationic Surfactants: Organic Chemistry, (Marcel Dekker, 1990).
• nonpolymeric primary stabilizers are any nonpolymeric compound, such benzalkonium chloride, a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quartemary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium compound, a primary ammonium compound, a secondary ammonium compound, a tertiary ammonium compound, and quartemary ammonium compounds of the formula NRiR 2 R 3 R 4 (+) .
• benzalkonium chloride a carbonium compound, a phosphonium compound, an oxonium compound, a halonium compound, a cationic organometallic compound, a quartemary phosphorous compound, a pyridinium compound, an anilinium compound, an ammonium compound, a hydroxylammonium
• Ri -R 4 two of Ri -R 4 are CH 3 , one of Ri-R is C 6 H 5 CH 2 , and one of R t -R 4 is an alkyl chain of nineteen carbon atoms or more;
• Such compounds include, but are not limited to, behenalkonium chloride, benzethonium chloride, cetylpyridinium chloride, behentrimonium chloride, lauralkonium chloride, cetalkonium chloride, cetrimonium bromide, cetrimonium chloride, cethylamine hydrofluoride, chlorallylmethenamine chloride (Quatemium-15), distearyldimonium chloride (Quatemium-5), dodecyl dimethyl ethylbenzyl ammonium chloride(Quaternium-14), Quaternium-22, Quatemium-26, Quatemium-18 hectorite, dimethylaminoethylchloride hydrochloride, cysteine hydrochloride, diethanolammonium POE (10) oletyl ether phosphate, diethanolammonium POE (3)oleyl ether phosphate, tallow alkonium chloride, dimethyl dioctadecylammoniumbento
• surface stabilizers are known pharmaceutical excipients and are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain (The Pharmaceutical Press, 2000), specifically incorporated by reference.
• the surface stabilizers are commercially available and/or can be prepared by techniques known in the art starting from known materials.
• the concentration of the at least one surface stabilizer can vary from about 0.001 to about 99.5%, from about 0.1% to about 95%, and from about 0.5% to about 90%, by weight, based on the total combined dry weight of the insulin and at least one surface stabilizer, not including other excipients.
• the insulin nanoparticles of the invention have an effective average particle size of less than about 5 microns, less than about 4 microns, less than about 3 microns, less than about 2 microns, less than about 1500 nm, less than about 1 micron, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm, as measured by light-scattering methods or other methods accepted in the art.
• an effective average particle size of less than about 5 microns it is meant that at least about 50% of the insulin particles have a weight average particle size of less than about 5 microns when measured by light scattering or other conventional techniques.
• at least about 70%, about 90%, or about 95% of the insulin particles have an effective average particle size of less than about 5 microns, less than about 4 microns, less than about 3 microns, less than about 2 microns, less than about 1500 nm, less than about 1 micron, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, less than about 75 nm, or less than about 50 nm.
• Nanoparticulate active agent compositions can be made using, for example, milling, or homogenization techniques. Exemplary methods of making nanoparticulate compositions are described in U.S. Patent No. 5,145,684. Methods of making nanoparticulate compositions are also described in U.S. Patent No. 5,518,187 for "Method of Grinding Pharmaceutical Substances;" U.S. Patent No. 5,718,388 for "Continuous Method of Grinding Pharmaceutical Substances;” U.S. Patent No. 5,862,999 for "Method of Grinding Pharmaceutical Substances;” U.S. Patent No.
• the optimal effective average particle size of the invention can be obtained by controlling the process of particle size reduction, such as by controlling the milling time and the amount of surface stabilizer added. Particle size growth and particle aggregation can also be minimized by milling and/or storing the composition under colder temperatures.
• nanoparticulate insulin dispersions made via, for example, milling or homogenization can be utilized in solid, semi-solid, or liquid dosage formulations, such as controlled release formulations, solid dose fast melt formulations, aerosol formulations, lyophilized formulations, tablets, solid lozenge, capsules, powders, liquids for injection, etc.
• Milling insulin to obtain a nanoparticulate composition comprises dispersing insulin particles in a liquid dispersion medium in which insulin is poorly soluble, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the insulin to the desired effective average particle size.
• the dispersion medium can be, for example, water, safflower oil, ethanol, t-butanol, glycerin, polyethylene glycol (PEG), hexane, or glycol.
• the insulin particles can be reduced in size in the presence of at least one surface stabilizer.
• the insulin particles can be contacted with one or more surface stabilizers after attrition. It is preferred, however, to disperse the insulin in the liquid dispersion medium in the presence of the at least one surface stabilizer as an aid in wetting of the insulin particles.
• Other compounds, such as a diluent, can be added to the insulin/surface stabilizer composition during the size reduction process. Dispersions can be manufactured continuously or in a batch mode.
• Such a method comprises dispersing insulin particles in a liquid dispersion medium, followed by subjecting the dispersion to homogenization to reduce the particle size of the insulin to the desired effective average particle size.
• the insulin particles can be reduced in size in the presence of at least one surface stabilizer.
• the insulin particles can be contacted with one or more surface stabilizers either before or after particle size reduction. It is preferred, however, to disperse the insulin in the liquid dispersion medium in the presence of the at least one surface stabilizer as an aid to wetting of the insulin particles.
• Other compounds, such as a diluent can be added to the insulin/surface stabilizer composition either before, during, or after the size reduction process.
• Dispersions can be manufactured continuously or in a batch mode.
• compositions in accordance with the present invention include nanoparticulate insulin compositions formulated together with one or more non-toxic, physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as carriers.
• Such carriers may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into such preparations.
• suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles include water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
• Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
• the nanoparticulate compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as potassium sorbate, methylparaben, propylparaben, benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl or benzyl alcohol, phenolic compounds such as phenol, or quartemary compounds such as benzalkonium chloride, parabens, chlorobutanol, phenol, sorbic acid, and the like.
• adjuvants such as preserving, wetting, emulsifying, and dispensing agents.
• the nanoparticulate compositions of the invention are intended for parenteral administration to humans and animals by known routes of parenteral administration, i.e., intravenous, intramuscular, subcutaneous, or intraperitoneal. Other dosage forms can also be utilized, such as aerosols, tablets, etc.
• nanoparticulate insulin compositions of the invention are given as standardized units of insulin as is the case with conventional insulin preparations and the dosage administered will depend on recognized factors such as the time of administration and the body weight, general health, age, sex, and diet of the patient.
• the purpose of this example was to prepare nanoparticulate insulin formulations using low energy milling techniques.
• Insulin and one or more surface stabilizers in the amounts shown in Table 1, were mixed with water to form a pre-milling slurry.
• This slurry was then added to a sealable vessel and rotated for from 1 to 4 days at a pre-set rotational speed (typically 100-200 rpm) on a roller mill using high wear zirconia grinding media (Tosoh Corporation, Tokyo, Japan) with a diameter of 0.8 mm.
• This low energy milling technique relies upon gravitational grinding mechanisms to break the particle size down, hence the use of heavy ceramic media.
• Particle size distributions of the resultant insulin compositions were determined using a Horiba LA-910 light-scattering particle size analyzer (Horiba Instruments, Irvine, CA). The results shown in Table 1 were determined at 24 hours post milling. It is to be noted that the concentration of insulin in this Example was 5%, but could have been, for example, 1%, 2%, 3%, or 10% or higher.
• the surface stabilizers used include: (1) poly (2-methacryloxyethyl-trimethylammonium bromide) (S1001); (2) poly(N-vinylpyrrolidone/2-dimethyl-aminoethyl methacrylate) dimethylsulphate quartemary (S1002); (3) poly(2-methylacryloxyamido- propyltrimethylammonium chloride) (S1004); (4) Pluronic® F68; (5) hydroxypropyl cellulose (HPC); (6) sodium deoxycholic acid; (7) vitamin E derivatized with polyethylene glycol (PEG); and (8) Tween® 80.
• S1001 poly (2-methacryloxyethyl-trimethylammonium bromide)
• S1002 poly(N-vinylpyrrolidone/2-dimethyl-aminoethyl methacrylate) dimethylsulphate quartemary
• S1004 poly(2-methylacryloxyamido- propyl
• the measurements reported in Table 2 were taken at one week post milling to determine stability for a representative group of the nanoparticulate compositions shown in Table 1.
• the particle size of the composition was smaller after one week than at 24 hours post milling.
• the stabilizer and drug particle may go through a thermodynamic relaxation period.
• Another theory is that in conjunction with relaxation or separately therefrom, there are interactions between the insulin particle and the stabilizer.
• a phenomenon may be occurring at the surface of the insulin particle that is similar to the use of cationic stabilizers to complex and condense DNA in solution, i.e. the stabilizer interaction may cause a slight condensation on the surface of the insulin particle, resulting in the observed reduction in particle size.
• the purpose of this example was to prepare nanoparticulate insulin formulations using high energy milling conditions.
• Samples of insulin were prepared using a high energy attrition media mill, NanoMillTM (Elan Drug Delivery, King of Prussia, PA).
• a high energy mill is designed to apply a much higher rotational velocity to the particulate dispersion (100-6000 rpm, typically 5000 rpm), than that used in low energy milling processes.
• the elevated rotational velocity imparts very high shear conditions within the milling chamber. It is this shear force which causes the particle size reduction.
• the media used in this milling technology is a much lighter, highly crosslinked polystyrene media.
• 500 ⁇ m media was used.
• Other media sizes that could be used range from 50 ⁇ m to 500 ⁇ m.
• the samples were milled from about 30 minutes up to about 3 hours.
• Particle size distributions were determined using a Horiba LA-910 light-scattering particle size analyzer (Horiba Instruments, Irvine, CA). Particle size was determined for all three compositions following milling, for Sample 2 at 24 hours following milling, and for Samples 1 and 2 at 1 week after milling. The results are shown in Table 3.
• the purpose of this example is to examine nanoparticle insulin prepared in accordance with the invention and test the stability of the compositions over an extended storage period.
• Nanoparticulate insulin was prepared in accordance with the procedure of Example 2. Milling was carried out until the insulin particles were found to have a mean particle size of 100 nm, with 90% of the particles less than 145 nm..
• FIG. 1 shows SEM images of insulin particles before and after milling, clearly demonstrating the effect of the milling and, more importantly, the capacity of the surface stabilizers to prevent agglomeration of the insulin particles. Analysis of a sample of this material stored for six months at 5°C revealed 90% of the insulin particles to be smaller than 145 nm.
• Example 4
• the purpose of this example was to determine the insulin content of a nanoparticulate composition following milling, and to determine if the milling process results in loss of insulin.
• Nanoparticulate insulin was prepared in accordance with the procedure of Example 1 from a slurry of 2% insulin having 1% Pluronic® F68 and 0.1% sodium deoxycholic acid as surface stabilizers.
• Reducing gels used in the analysis were prepared as 16% acrylamide gels and comprised 5.33 ml of acrylamide solution, 2.02 ml distilled water, 2.50 ml of 1.5 M TRIS buffer at pH of 8.8, 100 ⁇ m 10% SDS, 50 ⁇ m 10% ammonium persulfate, and 5 ⁇ m of TEMED (N,N,N',N- tetramethylethylene diamine). Reducing gels are useful for visualizing insulin bands, which appear as a dimer, tetramer, etc., and for identifying degraded insulin fragments.
• composition of the running buffer and loading buffers were as follows:
• the samples and the supernatant were diluted to 1:10 and 1:50, respectively, with sample buffer and then heated to 95°C for 5 mins before loading onto the gel.
• the volume of supernatant loaded was the amount that would be needed to load the required amount of sample, if the insulin were left in suspension.
• Lane 2 Sample supernatant 1:50 dilution
• Lane 3 Sample supernatant 1:10 dilution
• Lane 4 Pellet Sample 1:50 dilution
• Lane 5 Pellet Sample 1:10 dilution
• the reducing gel shown in FIG. 3 was loaded with the following:
• Lane 2 Pellet Sample 1:10 dilution
• Lane 3 Pellet Sample 1:50 dilution
• Lane 5 Raw Insulin Sample.
• the gels shown in FIGs 2 and 3 demonstrate that the pellet fraction of the milled insulin formulation contains all of the insulin.
• the lanes loaded with supernatant appear to be free of insulin. This indicates that all of the insulin in the nanoparticulate insulin composition is entrapped within or associated with the nanoparticulate composition, with little or no insulin free in solution. Thus, there is essentially 100% entrapment or association of the insulin within the nanoparticulate composition.
• the purpose of this example was to test the effectiveness of nanoparticulate insulin compositions parenterally administered, and to compare the effectiveness of the formulations with conventional raw insulin compositions.
• Blood glucose values for the rats were measured using an Accutren® alpha glucometer (Boehringer Mannhein) following systemic blood samples that were taken from the tail artery. A baseline blood sample was taken and samples were taken at intervals post injection up to four hours. Anesthesia was maintained throughout the study. A non-formulated insulin solution was utilized as a reference.
• the rat model used is a hypergylcemic model.
• the pharmacokinetic parameters of the test are given in FIG. 4. It can be seen from the results in FIG. 4 that the insulin compositions of the present invention are biologically active and at least approximately equal to the reference insulin solution.
• Fig. 5 illustrates the AUC ( ⁇ U/ml.h) for the sample by the three modes of parenteral administration in comparison to the reference insulin solution. The analysis shown in FIG. 5 likewise establishes the equivalence of the test preparation to the reference insulin solution.
• FIGs 6 and 7 are companion concentration-time profiles in that FIG 6 illustrates mean glucose concentration while FIG. 7 illustrates mean insulin concentration.
• the profiles in FIGs 6 and 7 clearly establish that the nanoparticulate insulin formulations of the invention are biologically active.
• the results reported in the figures demonstrate that the nanoparticulate insulin compositions of the present invention have excellent bioactivity following parenteral administration, which is at least equivalent to the reference insulin solution tested.
• the nanoparticle preparation of the present invention is advantageous over the reference insulin solution in maintaining a lowering of the blood glucose level over the duration of the test.
• a particular advantage can be seen from the comparison via intraperitoneal administration.

Landscapes

• Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Epidemiology (AREA)
• Diabetes (AREA)
• Endocrinology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Zoology (AREA)
• Gastroenterology & Hepatology (AREA)
• Immunology (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Emergency Medicine (AREA)
• Hematology (AREA)
• Obesity (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Peptides Or Proteins (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23259284

Family Applications (1)

Country Status (11)

Cited By (5)

Families Citing this family (59)

Citations (9)

Family Cites Families (85)

• 2002
  • 2002-09-19 EP EP02775863A patent/EP1429731B1/en not_active Expired - Lifetime
  • 2002-09-19 AT AT02775863T patent/ATE350013T1/de active
  • 2002-09-19 ES ES02775863T patent/ES2280582T3/es not_active Expired - Lifetime
  • 2002-09-19 DE DE60217367T patent/DE60217367T2/de not_active Expired - Lifetime
  • 2002-09-19 US US10/246,751 patent/US20030095928A1/en not_active Abandoned
  • 2002-09-19 CA CA2460867A patent/CA2460867C/en not_active Expired - Fee Related
  • 2002-09-19 JP JP2003528522A patent/JP4464129B2/ja not_active Expired - Fee Related
  • 2002-09-19 WO PCT/US2002/029679 patent/WO2003024425A1/en not_active Ceased
  • 2002-09-19 PT PT02775863T patent/PT1429731E/pt unknown
  • 2002-09-19 DK DK02775863T patent/DK1429731T3/da active
• 2007
  • 2007-01-26 US US11/698,151 patent/US20070122486A1/en not_active Abandoned
  • 2007-03-29 CY CY20071100434T patent/CY1106420T1/el unknown
• 2009
  • 2009-08-24 JP JP2009193163A patent/JP2010006826A/ja not_active Withdrawn

Patent Citations (10)

Also Published As

Similar Documents

Legal Events